Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 688

1.

An updated matrix to predict rapid radiographic progression of early rheumatoid arthritis patients: pooled analyses from several databases.

Vanier A, Smolen JS, Allaart CF, Vollenhoven RV, Verschueren P, Vastesaeger N, Saevarsdottir S, Visser K, Aletaha D, Combe B, Fautrel B.

Rheumatology (Oxford). 2019 Nov 13. pii: kez542. doi: 10.1093/rheumatology/kez542. [Epub ahead of print]

PMID:
31722413
2.

Preface.

Breedveld FC, Kalden JR, Smolen JS.

Semin Arthritis Rheum. 2019 Oct 31. pii: S0049-0172(19)30661-4. doi: 10.1016/j.semarthrit.2019.10.004. [Epub ahead of print] No abstract available.

PMID:
31706626
3.

Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial.

Strand V, Mysler E, Moots RJ, Wallenstein GV, DeMasi R, Gruben D, Soma K, Iikuni N, Smolen JS, Fleischmann R.

RMD Open. 2019 Oct 1;5(2):e001040. doi: 10.1136/rmdopen-2019-001040. eCollection 2019.

4.

Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019.

Winthrop KL, Weinblatt ME, Bathon J, Burmester GR, Mease PJ, Crofford L, Bykerk V, Dougados M, Rosenbaum JT, Mariette X, Sieper J, Melchers F, Cronstein BN, Breedveld FC, Kalden J, Smolen JS, Furst D.

Ann Rheum Dis. 2019 Oct 29. pii: annrheumdis-2019-216151. doi: 10.1136/annrheumdis-2019-216151. [Epub ahead of print]

5.

Determinants of Patient-Reported Psoriatic Arthritis Impact of Disease: An Analysis of the Association with Gender in 458 Patients from 14 Countries.

Orbai AM, Perin J, Gorlier C, Coates LC, Kiltz U, Leung YY, Palominos PE, Cañete JD, Scrivo R, Balanescu A, Dernis E, Tälli S, Ruyssen-Witrand A, Soubrier M, Aydin S, Eder L, Gaydukova I, Lubrano E, Kalyoncu U, Richette P, Husni ME, Smolen JS, de Wit M, Gossec L.

Arthritis Care Res (Hoboken). 2019 Oct 14. doi: 10.1002/acr.24090. [Epub ahead of print]

PMID:
31609525
6.

Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remission.

Aletaha D, Wang X, Zhong S, Florentinus S, Monastiriakos K, Smolen JS.

Semin Arthritis Rheum. 2019 Sep 19. pii: S0049-0172(19)30286-0. doi: 10.1016/j.semarthrit.2019.09.005. [Epub ahead of print]

PMID:
31590930
7.

Etanercept therapy leads to reductions in matrix metalloproteinase-3 in patients with erosive hand osteoarthritis.

Kroon F, Bay-Jensen AC, Wittoek R, Verbruggen G, Smolen JS, Kloppenburg M, Ramonda R.

Scand J Rheumatol. 2019 Sep 30:1-2. doi: 10.1080/03009742.2019.1657493. [Epub ahead of print] No abstract available.

PMID:
31566063
8.

Treat to Target in Rheumatology: A Historical Account on Occasion of the 10th Anniversary.

Smolen JS.

Rheum Dis Clin North Am. 2019 Nov;45(4):477-485. doi: 10.1016/j.rdc.2019.07.001. Epub 2019 Aug 16. Review.

PMID:
31564291
9.

A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial.

Mease PJ, Smolen JS, Behrens F, Nash P, Liu Leage S, Li L, Tahir H, Gooderham M, Krishnan E, Liu-Seifert H, Emery P, Pillai SG, Helliwell PS; SPIRIT H2H study group.

Ann Rheum Dis. 2019 Sep 28. pii: annrheumdis-2019-215386. doi: 10.1136/annrheumdis-2019-215386. [Epub ahead of print]

10.

Rheumatoid arthritis disease activity and the risk of aseptic arthroplasty loosening.

Böhler C, Weimann P, Alasti F, Smolen JS, Windhager R, Aletaha D.

Semin Arthritis Rheum. 2019 Aug 1. pii: S0049-0172(19)30374-9. doi: 10.1016/j.semarthrit.2019.07.011. [Epub ahead of print]

PMID:
31471012
11.

Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis.

Aletaha D, Maa JF, Chen S, Park SH, Nicholls D, Florentinus S, Furtner D, Smolen JS.

Ann Rheum Dis. 2019 Dec;78(12):1609-1615. doi: 10.1136/annrheumdis-2018-214918. Epub 2019 Aug 21.

12.

Remission in rheumatoid arthritis: missing objectives by using inadequate DAS28 targets.

Aletaha D, Smolen JS.

Nat Rev Rheumatol. 2019 Nov;15(11):633-634. doi: 10.1038/s41584-019-0279-6. No abstract available.

PMID:
31427763
13.

2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus.

Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirják L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Fernández Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Dörner T, Johnson SR.

Arthritis Rheumatol. 2019 Sep;71(9):1400-1412. doi: 10.1002/art.40930. Epub 2019 Aug 6.

PMID:
31385462
14.

2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus.

Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirják L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Fernández Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Dörner T, Johnson SR.

Ann Rheum Dis. 2019 Sep;78(9):1151-1159. doi: 10.1136/annrheumdis-2018-214819. Epub 2019 Aug 5. Review.

15.

Analysis of gene expression in rheumatoid arthritis and related conditions offers insights into sex-bias, gene biotypes and co-expression patterns.

Platzer A, Nussbaumer T, Karonitsch T, Smolen JS, Aletaha D.

PLoS One. 2019 Jul 25;14(7):e0219698. doi: 10.1371/journal.pone.0219698. eCollection 2019.

16.

IRF1 is critical for the TNF-driven interferon response in rheumatoid fibroblast-like synoviocytes : JAKinibs suppress the interferon response in RA-FLSs.

Bonelli M, Dalwigk K, Platzer A, Olmos Calvo I, Hayer S, Niederreiter B, Holinka J, Sevelda F, Pap T, Steiner G, Superti-Furga G, Smolen JS, Kiener HP, Karonitsch T.

Exp Mol Med. 2019 Jul 8;51(7):75. doi: 10.1038/s12276-019-0267-6.

17.

Does Triple Conventional Synthetic Disease-Modifying Antirheumatic Drug Therapy Improve upon Methotrexate as the Initial Treatment of Choice for a Rheumatoid Arthritis Patient?

Aletaha D, Smolen JS.

Rheum Dis Clin North Am. 2019 Aug;45(3):315-324. doi: 10.1016/j.rdc.2019.04.002. Epub 2019 Jun 5. Review.

PMID:
31277746
18.

The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis.

Tanaka Y, Smolen JS, Jones H, Szumski A, Marshall L, Emery P.

Arthritis Res Ther. 2019 Jul 5;21(1):164. doi: 10.1186/s13075-019-1937-4.

19.

MicroRNA-155 Controls T Helper Cell Activation During Viral Infection.

Goncalves-Alves E, Saferding V, Schliehe C, Benson R, Kurowska-Stolarska M, Brunner JS, Puchner A, Podesser BK, Smolen JS, Redlich K, Bonelli M, Brewer J, Bergthaler A, Steiner G, Blüml S.

Front Immunol. 2019 Jun 13;10:1367. doi: 10.3389/fimmu.2019.01367. eCollection 2019.

20.

Impact of flare on radiographic progression after etanercept continuation, tapering or withdrawal in patients with rheumatoid arthritis.

Smolen JS, Pedersen R, Jones H, Mahgoub E, Marshall L.

Rheumatology (Oxford). 2019 Jun 30. pii: kez224. doi: 10.1093/rheumatology/kez224. [Epub ahead of print]

PMID:
31257453
21.

Era of biosimilars in rheumatology: reshaping the healthcare environment.

Smolen JS, Goncalves J, Quinn M, Benedetti F, Lee JY.

RMD Open. 2019 May 21;5(1):e000900. doi: 10.1136/rmdopen-2019-000900. eCollection 2019. Review.

22.

Relative Impact of Pain and Fatigue on Work Productivity in Patients with Rheumatoid Arthritis from the RA-BEAM Baricitinib Trial.

Michaud K, Pope JE, Emery P, Zhu B, Gaich CL, DeLozier AM, Zhang X, Dickson CL, Smolen JS.

Rheumatol Ther. 2019 Sep;6(3):409-419. doi: 10.1007/s40744-019-0164-4. Epub 2019 Jun 21.

23.

Disease activity assessment in patients with psoriatic arthritis.

Kerschbaumer A, Smolen JS, Aletaha D.

Best Pract Res Clin Rheumatol. 2018 Jun;32(3):401-414. doi: 10.1016/j.berh.2018.08.004. Epub 2018 Oct 11. Review.

PMID:
31171311
24.

Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study.

Smolen JS, Pangan AL, Emery P, Rigby W, Tanaka Y, Vargas JI, Zhang Y, Damjanov N, Friedman A, Othman AA, Camp HS, Cohen S.

Lancet. 2019 Jun 8;393(10188):2303-2311. doi: 10.1016/S0140-6736(19)30419-2. Epub 2019 May 23. Erratum in: Lancet. 2019 Jun 29;393(10191):2590.

PMID:
31130260
25.

Greetings from the editor.

Smolen JS.

Ann Rheum Dis. 2019 Jun;78(6):715. doi: 10.1136/annrheumdis-2019-215621. No abstract available.

PMID:
31088798
26.

Multimodal [18 F]FDG PET/CT Is a Direct Readout for Inflammatory Bone Repair: A Longitudinal Study in TNFα Transgenic Mice.

Hayer S, Zeilinger M, Weiss V, Dumanic M, Seibt M, Niederreiter B, Shvets T, Pichler F, Wadsak W, Podesser BK, Helbich TH, Hacker M, Smolen JS, Redlich K, Mitterhauser M.

J Bone Miner Res. 2019 Sep;34(9):1632-1645. doi: 10.1002/jbmr.3748. Epub 2019 Jul 30.

PMID:
31063606
27.

Effects of a brief workplace-centered consultation for employees with musculoskeletal pain on health outcomes: a prospective cohort study.

Leiss H, Hucke M, Bécède M, Machold-Fabrizii V, Smolen JS, Machold KP.

Sci Rep. 2019 Apr 10;9(1):5867. doi: 10.1038/s41598-019-42387-4.

28.

Genetic markers associated with clinical and radiographic response in adalimumab plus methotrexate- or methotrexate-treated rheumatoid arthritis patients in OPTIMA.

Skapenko A, Smolen JS, Kavanaugh A, Arora V, Kupper H, Schulze-Koops H.

Clin Exp Rheumatol. 2019 Sep-Oct;37(5):783-790. Epub 2019 Apr 9.

29.

2019 update of the EULAR recommendations for the management of systemic lupus erythematosus.

Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, Cervera R, Doria A, Gordon C, Govoni M, Houssiau F, Jayne D, Kouloumas M, Kuhn A, Larsen JL, Lerstrøm K, Moroni G, Mosca M, Schneider M, Smolen JS, Svenungsson E, Tesar V, Tincani A, Troldborg A, van Vollenhoven R, Wenzel J, Bertsias G, Boumpas DT.

Ann Rheum Dis. 2019 Jun;78(6):736-745. doi: 10.1136/annrheumdis-2019-215089. Epub 2019 Mar 29.

PMID:
30926722
30.

Risk profiling for a refractory course of rheumatoid arthritis.

Bécède M, Alasti F, Gessl I, Haupt L, Kerschbaumer A, Landesmann U, Loiskandl M, Supp GM, Smolen JS, Aletaha D.

Semin Arthritis Rheum. 2019 Oct;49(2):211-217. doi: 10.1016/j.semarthrit.2019.02.004. Epub 2019 Feb 8.

31.

Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials.

Harigai M, Takeuchi T, Smolen JS, Winthrop KL, Nishikawa A, Rooney TP, Saifan CG, Issa M, Isaka Y, Akashi N, Ishii T, Tanaka Y.

Mod Rheumatol. 2019 Feb 20:1-8. doi: 10.1080/14397595.2019.1583711. [Epub ahead of print]

PMID:
30784354
32.

Achieving Clinical Remission for Patients With Rheumatoid Arthritis.

Aletaha D, Smolen JS.

JAMA. 2019 Feb 5;321(5):457-458. doi: 10.1001/jama.2018.21249. No abstract available.

PMID:
30721278
33.

Predicting adherence to therapy in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis: a large cross-sectional study.

Smolen JS, Gladman D, McNeil HP, Mease PJ, Sieper J, Hojnik M, Nurwakagari P, Weinman J.

RMD Open. 2019 Jan 11;5(1):e000585. doi: 10.1136/rmdopen-2017-000585. eCollection 2019.

34.

Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018.

Winthrop KL, Weinblatt ME, Crow MK, Burmester GR, Mease PJ, So AK, Bykerk V, Van Vollenhoven RF, Dougados M, Kay J, Mariette X, Sieper J, Melchers F, Cronstein BN, Shevach E, Breedfeld FC, Kalden J, Smolen JS, Furst DE.

Ann Rheum Dis. 2019 Jul;78(7):872-878. doi: 10.1136/annrheumdis-2018-214280. Epub 2019 Feb 2. Review.

PMID:
30712015
35.

I would never take preventive medication! Perspectives and information needs of people who underwent predictive tests for rheumatoid arthritis.

Mosor E, Stoffer-Marx M, Steiner G, Raza K, Stack RJ, Simons G, Falahee M, Skingle D, Dobrin M, Schett G, Englbrecht M, Smolen JS, Kjeken I, Hueber AJ, Stamm TA.

Arthritis Care Res (Hoboken). 2019 Feb 2. doi: 10.1002/acr.23841. [Epub ahead of print]

PMID:
30710453
36.

Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus.

Tedeschi SK, Johnson SR, Boumpas DT, Daikh D, Dörner T, Diamond B, Jacobsen S, Jayne D, Kamen DL, McCune WJ, Mosca M, Ramsey-Goldman R, Ruiz-Irastorza G, Schneider M, Urowitz M, Wofsy D, Smolen JS, Naden RP, Aringer M, Costenbader KH.

Ann Rheum Dis. 2019 May;78(5):634-640. doi: 10.1136/annrheumdis-2018-214685. Epub 2019 Jan 28.

37.

FOXO3 is involved in the tumor necrosis factor-driven inflammatory response in fibroblast-like synoviocytes.

Brandstetter B, Dalwigk K, Platzer A, Niederreiter B, Kartnig F, Fischer A, Vladimer GI, Byrne RA, Sevelda F, Holinka J, Pap T, Steiner G, Superti-Furga G, Smolen JS, Kiener HP, Karonitsch T.

Lab Invest. 2019 May;99(5):648-658. doi: 10.1038/s41374-018-0184-7. Epub 2019 Jan 24.

PMID:
30679758
38.

Identifying Provisional Generic Contextual Factor Domains for Clinical Trials in Rheumatology: Results from an OMERACT Initiative.

Nielsen SM, Tugwell P, de Wit MPT, Boers M, Beaton DE, Woodworth TG, Escorpizo R, Shea B, Toupin-April K, Guillemin F, Strand V, Singh JA, Kloppenburg M, Furst DE, Wells GA, Smolen JS, Veselý R, Boonen A, Storgaard H, Voshaar M, March L, Christensen R; Contextual Factors Working Group.

J Rheumatol. 2019 Sep;46(9):1159-1163. doi: 10.3899/jrheum.181081. Epub 2019 Jan 15.

PMID:
30647174
39.

Greetings from the editor 2019.

Smolen JS.

Ann Rheum Dis. 2019 Jan;78(1):1-2. doi: 10.1136/annrheumdis-2018-214822. No abstract available.

PMID:
30563867
40.

Use of Consensus Methodology to Determine Candidate Items for Systemic Lupus Erythematosus Classification Criteria.

Johnson SR, Khanna D, Daikh D, Cervera R, Costedoat-Chalumeau N, Gladman DD, Hahn BH, Hiepe F, Sánchez-Guerrero J, Massarotti E, Boumpas DT, Costenbader KH, Jayne D, Dörner T, Kamen DL, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Aringer M.

J Rheumatol. 2019 Jul;46(7):721-726. doi: 10.3899/jrheum.180478. Epub 2018 Dec 15.

PMID:
30554156
41.

Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD study.

Norvang V, Sexton J, Kristianslund EK, Olsen IC, Uhlig T, Bakland G, Krøll F, Rødevand E, Wierød A, Kvien TK, Smolen JS, Aletaha D, Haavardsholm EA.

RMD Open. 2018 Oct 26;4(2):e000773. doi: 10.1136/rmdopen-2018-000773. eCollection 2018.

42.

Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries.

Gorlier C, Orbai AM, Puyraimond-Zemmour D, Coates LC, Kiltz U, Leung YY, Palominos P, Cañete JD, Scrivo R, Balanescu A, Dernis E, Tälli S, Ruyssen-Witrand A, Soubrier M, Aydin SZ, Eder L, Gaydukova I, Lubrano E, Kalyoncu U, Richette P, Husni ME, de Wit M, Smolen JS, Gossec L.

Ann Rheum Dis. 2019 Feb;78(2):201-208. doi: 10.1136/annrheumdis-2018-214140. Epub 2018 Nov 15.

43.

Functional consultation and exercises improve grip strength in osteoarthritis of the hand - a randomised controlled trial.

Stoffer-Marx MA, Klinger M, Luschin S, Meriaux-Kratochvila S, Zettel-Tomenendal M, Nell-Duxneuner V, Zwerina J, Kjeken I, Hackl M, Öhlinger S, Woolf A, Redlich K, Smolen JS, Stamm TA.

Arthritis Res Ther. 2018 Nov 9;20(1):253. doi: 10.1186/s13075-018-1747-0.

44.

I do not want to suppress the natural process of inflammation: new insights on factors associated with non-adherence in rheumatoid arthritis.

Ritschl V, Lackner A, Boström C, Mosor E, Lehner M, Omara M, Ramos R, Studenic P, Smolen JS, Stamm TA.

Arthritis Res Ther. 2018 Oct 19;20(1):234. doi: 10.1186/s13075-018-1732-7.

45.

Diagnosis and Management of Rheumatoid Arthritis: A Review.

Aletaha D, Smolen JS.

JAMA. 2018 Oct 2;320(13):1360-1372. doi: 10.1001/jama.2018.13103. Review.

PMID:
30285183
46.

Etanercept in patients with inflammatory hand osteoarthritis (EHOA): a multicentre, randomised, double-blind, placebo-controlled trial.

Kloppenburg M, Ramonda R, Bobacz K, Kwok WY, Elewaut D, Huizinga TWJ, Kroon FPB, Punzi L, Smolen JS, Vander Cruyssen B, Wolterbeek R, Verbruggen G, Wittoek R.

Ann Rheum Dis. 2018 Dec;77(12):1757-1764. doi: 10.1136/annrheumdis-2018-213202. Epub 2018 Oct 3.

PMID:
30282670
47.

Can disease activity in patients with psoriatic arthritis be adequately assessed by a modified Disease Activity index for PSoriatic Arthritis (DAPSA) based on 28 joints?

Michelsen B, Sexton J, Smolen JS, Aletaha D, Krogh NS, van der Heijde D, Kvien TK, Hetland ML.

Ann Rheum Dis. 2018 Dec;77(12):1736-1741. doi: 10.1136/annrheumdis-2018-213463. Epub 2018 Sep 20.

PMID:
30237203
48.

Adverse Events and Resource Use Before and After Treat-to-Target in Rheumatoid Arthritis: A Post Hoc Analysis of a Randomized Controlled Trial.

Solomon DH, Yu Z, Katz JN, Bitton A, Corrigan C, Fraenkel L, Harrold LR, Smolen JS, Losina E, Lu B.

Arthritis Care Res (Hoboken). 2019 Sep;71(9):1243-1248. doi: 10.1002/acr.23755. Epub 2019 Jul 19.

PMID:
30221841
49.

Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment.

Smolen JS, Genovese MC, Takeuchi T, Hyslop DL, Macias WL, Rooney T, Chen L, Dickson CL, Riddle Camp J, Cardillo TE, Ishii T, Winthrop KL.

J Rheumatol. 2019 Jan;46(1):7-18. doi: 10.3899/jrheum.171361. Epub 2018 Sep 15.

50.

Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study.

Takeuchi T, Genovese MC, Haraoui B, Li Z, Xie L, Klar R, Pinto-Correia A, Otawa S, Lopez-Romero P, de la Torre I, Macias W, Rooney TP, Smolen JS.

Ann Rheum Dis. 2019 Feb;78(2):171-178. doi: 10.1136/annrheumdis-2018-213271. Epub 2018 Sep 7.

Supplemental Content

Loading ...
Support Center